Delanzomib

Delanzomib (CAS 847499-27-8, formula C21H28BN3O5) is a boronic acid-based proteasome inhibitor developed under the research codes CEP-18770, CS-252, and CT-47098. It belongs to the class of pharmaceutical intermediates and active pharmaceutical ingredients targeting the ubiquitin-proteasome pathway. No E-code or EC number is assigned.

Delanzomib is investigated primarily in oncology research, where it inhibits the 26S proteasome's chymotrypsin-like activity, disrupting protein degradation and triggering apoptosis in malignant cells. It has been studied in multiple myeloma and solid tumour models, and serves as a reference compound or synthetic building block in proteasome inhibitor drug development programmes.

Delanzomib is supplied as a solid for research and pharmaceutical development use, handled under REACH compliance requirements applicable to European importers and downstream users. Procurement teams should confirm purity grade, certificate of analysis, and GMP or non-GMP status with the supplier prior to order. HS code 29333990 applies for customs classification.